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Abstract
Background: Burkholderia pseudomallei are the causative agent of melioidosis. Increasing resistance
of the disease to antibiotics is a severe problem in treatment regime and has led to intensification
of the search for new drugs. Antimicrobial peptides are the most ubiquitous in nature as part of
the innate immune system and host defense mechanism.
Methods: Here, we investigated a group of venoms (snakes, scorpions and honey bee venoms) for
antimicrobial properties against two strains of Gram-negative bacteria Burkholderia pseudomallei by
using disc-diffusion assay for in vitro susceptibility testing. The antibacterial activities of the venoms
were compared with that of the isolated L-amino acid oxidase (LAAO) and phospholipase A2
(PLA2s)  e n z y m e s .  M I C s  w e r e  d e t e rmined using broth dilution method. Bacterial growth was
assessed by measurement of optical density at the lowest dilutions (MIC 0.25 mg/ml). The cell
viability was measured using tetrazolium salts (XTT) based cytotoxic assay.
Results: The studied venoms showed high antimicrobial activity. The venoms of C. adamanteus,
Daboia russelli russelli, A. halys, P. australis, B. candidus and P. guttata were equally as effective as
Chloramphenicol and Ceftazidime (30 μg/disc). Among those tested, phospholipase A2 enzymes
(crotoxin B and daboiatoxin) showed the most potent antibacterial activity against Gram-negative
(TES) bacteria. Naturally occurring venom peptides and phospholipase A2 proved to possess highly
potent antimicrobial activity against Burkholderia pseudomallei. The XTT-assay results showed that
the cell survival decreased with increasing concentrations (0.05–10 mg/mL) of Crotalus adamanteus
venom, with no effect on the cell viability evident at 0.5 mg/mL.
Conclusion: This antibacterial profile of snake venoms reported herein will be useful in the search
for potential antibacterial agents against drug resistant microorganisms like B. pseudomallei.
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Background
Gram-negative  Burkholderia pseudomallei, the causative
agent of melioidosis, are found widely in soil and surface
water throughout the tropics. High incidence of melioido-
sis has been found particularly in Southeast Asia and
Northern Australia [1,2]. A number of cases have been
reported in Malaysia [3], Thailand [4], Northern Australia
[5], South China [6], Taiwan [7], South India, Africa and
America. The majority of adult patients develop acute pul-
monary or septicaemic illness with high mortality rates
[8], or subacute melioidosis, characterized by multiple-
abscess formation. In cases of septicaemic melioidosis,
which is associated with a vigorous inflammatory
cytokine response [9], septic shock continues to be a
major cause of morbidity and mortality in patients.
Tumor necrosis factor (TNF) is involved in the acquisition
of melioidosis, and is also related to disease severity [10].
Antibiotic resistance has been of great concern during the
last decades due to the extensive clinical use of classical
antibiotics [11]. Currently available antimicrobials fail to
lower the mortality rate of melioidosis [12,13]. B. pseu-
domallei demonstrate high levels of resistance to the action
of cationic antimicrobial peptides such as polylysine, pro-
tamine sulfate, human neutrophil peptides (HNP-1), and
polymyxins [14,15]. Therefore, it is of considerable inter-
est to develop antimicrobials with a new mechanism(s) of
action which can potentially evade the emergence of drug
resistance. In the search for such new agents, we are look-
ing for effective bactericidal peptides from multi-cellular
animals that have potential activity against B. pseudomal-
lei. The antimicrobial peptides are ubiquitous in nature as
part of the innate immune system and host defence mech-
anisms. They have been increasingly recognized as a criti-
cal first line of defence against many pathogens isolated
from various sources [16].
Proteinacious components such as neurotoxin, cytotoxin,
myotoxin, protease and nuclease are found in varying
quantities in snake venoms depending on the species. It
has been reported that the basic myotoxic PLA2 enzymes,
(myotoxin II) of Bothrops asper [17] and BnpTx I of Both-
rops neuwiedi pauloensis [18], possess bactericidal activity
against  E. coli and  S. aureus. The crude venom and
enzymes (LAAO1 and LAAO2) from Pseudechis australis
are also known to have antibacterial effects against gram
(+) and gram (-) bacteria [19]. Besides the strong haemo-
lytic activity shown against sheep erythrocytes, the
magainin-type polycationic antimicrobial peptides
(pandinin 1 & 2) from the venom of African scorpion
Pandinus imperator demonstrate high antimicrobial activ-
ity against a range of gram (+) and gram (-) bacteria [20].
Moreover, anti-bacterial peptides called the cecropins and
defensins have been identified in the hemolymph of scor-
pions [21]. They are active against bacteria through lysis of
their cells thus causing death of the microorganisms. Bac-
tericidal peptides (lycotoxins) have also been identified in
the venom of the spider Lycosa singoriensis [22], while
another family of peptides (cupiennius) with bactericidal
activity has been isolated from the venom of a different
species of Cupiennius salei [23]. Melittin is an important
venom component of Apis mellifera (common honey bee)
which is more active against gram (+) and gram (-) bacte-
ria [24,25]. The highly cationic and salt insensitive cathe-
licidins of mammalian origin are also reported to have a
broad-spectrum of antimicrobial activities [26]. The pep-
tides differ widely in sequence and structure, yet kill bac-
teria by thinning and disrupting the bacterial membrane
[27], and as a result these peptides are important as
unique source leads for the development of new therapeu-
tic agents [28]. The above examples thus emphasize the
fact that animal toxins or peptides can be rich sources of
antimicrobials which may be useful as therapeutics in
human.
Although a large number of bioactive components have
previously been isolated and characterized from snake
venoms, no systematic search for antibacterial compo-
nents from animal venoms has yet been reported. In our
previous studies, majority of the venoms exerted a broad
spectrum of antimicrobial activity against various gram-
negative and gram-positive bacteria (Journal of Applied
Microbiology – under revision). We describe here the
antimicrobial properties of 34 different venoms of scorpi-
ons, snakes and honey bee, along with those of nine puri-
fied venom phospholipase A2  enzymes and two L-
aminoacid oxidase, evaluated against multi-drug resistant
pathogen obtained from the patient with melioidosis (B.
pseudomallei strains KHW and TES).
Methods
Venoms
Lyophilized venoms – Acanthophis augtra, Acanthophis ant-
arcticus, Acanthophis praelongus, Acanthophis Pyrrhus,
Androctonus australis, Bungarus candidus, Hyrophis cyanoc-
inctus, Naja naja naja, Notechis aterater, Naja sumatrana,
Naja kaouthia, Pseudechis australis, Pseudechis guttata, Pseu-
dechis porphyriacus, Pseudechis colletti, Pseudonaja inframag-
gula, Pseudonaja nuchalis, Pseudonaja textilis, Pseudechis
affinis, Rhabdophis tigrinus, Oxyuranus scutellatus, Agkistro-
don halys, Bitis gabonica rhinoceros, Crotalus adamanteus,
Echis carinatus, Daboia russelli russelli, Daboia russelli sia-
mensis, Trimeresurus wagleri, Apis mellifera, Bothotus hotten-
lota, Buthotus hottenota hottenota, Buthus martensii and Naja
naja naja venoms were extracted from long-term captive
specimens. Venoms from captive specimens were col-
lected manually by milking. Each sample of freeze-dried
venom was stored at 4°C. The solid venoms were
obtained from commercial sources (Venom supplies Pte
Ltd, Tanunda, South Australia). L-amino acid oxidaseBMC Infectious Diseases 2006, 6:100 http://www.biomedcentral.com/1471-2334/6/100
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purified from the venom of B. atrox and C. adamanteus
were obtained commercially (Sigma Aldrich, St Louis,
MO, USA).
Antibacterial effects of venoms
Each sample of freeze-dried venom was dissolved in 1 mL
of 50 mM Tris-HCl buffer (pH 7.4), vortexed (Labnet
VX100), and filtered using 0.22 mμ syringe filter (Milli-
pore, NY, USA) before storage at 4°C. All the venoms were
tested for their antibacterial activity against gram-negative
bacteria Burkholderia pseudomallei (KHW) and Burkholderia
pseudomallei  (TES) by disc-diffusion susceptibility tests
were performed following standards recommended by the
NCCLS [29] with some modifications. Bacterial inocu-
lums (200 μL of a 0.1 A600 culture containing 3.2 × 108
colony forming units cfu/mL) were spread by using a ster-
ile cotton swab onto 20 mL of sterile TS agar plates (90
mm diameter). The surface of the medium was allowed to
dry for about 3 min. Sterile paper discs (7 mm diameter)
were then placed onto the TS agar surface and 20 μL (0.1
mg/mL) of venom sample was added per disc in 5 repli-
cates. Disc containing 20 μL of Tris-HCl buffer served as a
normal control and discs containing antibiotics were used
as drug controls. The plates were incubated at 37°C for 24
h, following which the diameter of inhibition zones were
measured and calculated, and the resultant activities com-
pared with purified PLA2 enzymes.
Purification of phospholipase A2 (PLA2) enzymes
Phospholipase A2 enzymes were purified from their corre-
sponding crude venoms as described [30] with minor
modification. In brief, the venom (0.4 g/4 ml) was frac-
tionated on a Superdex-G75 column with Tris-HCl buffer
(50 mM, pH 7.4) as an eluant, followed by further purifi-
cation on a RP-HPLC Jupiter C18 column (AKTA explorer
Workstation, Amersham Pharmacia Biotech, Sweden),
eluted with a linear gradient of 80% acetonitrile in 0.1%
trifluoroacetic acid. Elution of proteins was monitored at
280 nm and 215 nm. The homogeneity of purified PLA2s
was determined by using MALDI-TOF on a Voyager DE-
STR Biospectrometry workstation (Applied Biosystem CA,
USA).
Antibacterial effects of purified PLA2
All the venom enzymes used in the experiment have been
purified by successive chromatographic steps with the
final purity of at least 95% as assessed by Reversed-phase
HPLC. The activities of the following phospholipase A2
enzymes purified from the venoms of different snake spe-
cies (in parenthesis) – crotoxin A (Crotalus durissus terrifi-
cus), crotoxin B (Crotalus durissus terrificus), ammodytoxin
A (Vipera ammodytes ammodytes), mojavetoxin (Crotalus
scutulatus scutulatus), β-bungarotoxin (Bungarus multicinc-
tus), taipoxin (Oxyuranus scutellatus scutellatus), mulga-
toxin (Pseudechis australis),  Daboiatoxin  (Daboia russelli
russelli), honey bee (Apis mellifera) venom phospholipase
A2 – and two L-amino acid oxidase – LAAO (B. atrox),
LAAO (C. adamanteus) were evaluated. 0.5 μmoles of each
of the enzyme dissolved in 500 μL of 50 mM Tris-HCl
(pH7.4) buffer was examined. In vitro antimicrobial activ-
ity was determined by the previously described disc-diffu-
sion method [29] with some modifications.
MIC determinations
In preliminary experiments, the disc-diffusion assay for
determining antibacterial effects of crude venoms was
compared to the activity of isolated phospholipase A2
(PLA2) enzymes using broth-microdilution method. Dif-
ferences in data between these two assays were observed.
Thus, we used the broth-microdilution technique to test
the activities of the phospholipase A2 against pathogen
from patients by comparing their activities to the activity
of the antibiotics. Bacteria from frozen suspensions were
sub-cultured onto Tryptic soya (TS) agar plates and pas-
saged twice prior to susceptibility testing. The bacteria
were grown in Tryptic soy broth (TSB) for 5 – 7 h (expo-
nential phase) before adjusting their concentration to a
0.5 McFarland turbidity standard. The adjusted bacterial
cultures were diluted to approximately (A600 of 0.8) 3.2 ×
108 colony forming units (cfu/mL). The enzymes (PLA2S)
to be examined were dissolved in 1 M Tris-HCl buffer (pH
7.4) for determination of the activities (MIC). The bacte-
ria were washed and incubated with the enzymes in
appropriate buffer. MICs were determined by the broth
microdilution method recommended by the NCCLS
[31,32], for which serial dilutions of each enzyme solu-
tions were prepared (final concentration 0.5, 0.25, 0.125,
0.0625 and 0.03125 mg/mL) in microtiter trays with
appropriate medium (TSB). Each dilution series included
control wells containing bacteria without enzymes. A total
of 200 μL of the adjusted inoculum of 105 cfu/mL was
added to each well (96-well plates). The culture trays were
incubated at 37°C for 24 h with shaking at 230 rpm. The
inhibition of bacterial growth was determined by measur-
ing the absorbance at 560 nm (Molecular Devices E preci-
sion microplate reader). The MIC was taken as the lowest
concentration of phospholipase A2 enzyme that inhibited
visible growth of the organism. The results given are mean
values of three independent determinations.
Biochemical characterization
Phospholipase A2 enzyme activity
Phospholipase A2 (PLA2) catalyzes the hydrolysis of phos-
pholipids at the sn-2 position yielding a free fatty acid and
a lysophospholipid. The Cayman Chemical secretory
PLA2 (sPLA2) assay kit was used for the measurement of
enzyme activity. This assay uses the 1, 2-dithio analog of
diheptanoyl phosphatidylcholine which serves as a sub-
strate for most PLA2s [33]. sPLA2  specific activity is
expressed as μmole/min/mg protein.BMC Infectious Diseases 2006, 6:100 http://www.biomedcentral.com/1471-2334/6/100
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Protein assay
The protein concentration of the crude venom solutions
was determined using the Bio-Rad protein assay reagent
[34] and bovine serum albumin as a standard.
Cell Proliferation assay (XTT-based cytotoxicity assay)
The human macrophage cell line (U-937) was purchased
from ATCC (Virginia, USA) and cell Proliferation Kit II
was from Roche Applied Sciences (Singapore). Sterile
Roswell Park Memorial Institute (RPMI) medium, Fetal
Bovine Serum (FBS), 1 M Tris-HCl buffer (pH 7.4), and 10
mM HEPES were purchased from National University
Medical Institute (NUMI), Singapore. All chemicals were
of analytical and cell culture grade. Human macrophage
(U-937) cell line was cultured in 72 cm2 flasks at a density
of 1 × 107cells/12 mL in RPMI culture medium supple-
mented with 10% fetal bovine serum (FBS), and 1 ml of
HEPES. The cell viability was measured using tetrazolium
salts (XTT) as described [35]. Briefly, the cells were
allowed to adhere to the bottom of the flask for overnight
at 37°C in a humidified atmosphere of 5% CO2 and 95%
air. The culture medium was changed three times a week.
To analyze the initial events of venom-mediated cell via-
bility, five different venoms were applied to cultured mac-
rophage cell lines with each venom tested at different
concentrations (0.05 – 10 mg/mL) and varied time inter-
vals (12, 24, and 48 h). Cell proliferation was spectropho-
tometrically quantified using an ELISA plate reader at 490
nm. All assays were prepared in triplicates and repeated
thrice. The cytotoxicity of purified PLA2 enzymes was also
tested at different concentrations (0.05–10 μg/mL) using
XTT assay.
Statistical analysis
The results (mean ± S.D, n = 5) were analysed by one way-
ANOVA with repeated measures to analyze factors influ-
encing the zone size of growth inhibition, and for com-
parison with standard drugs.
Results and discussion
In the present study, both the strains of B. pseudomallei
(KHW & TES) proved to be highly or intermediately sus-
ceptible to various snake venoms at the tested concentra-
tion (Table 1). The venom from crotalid (C. adamanteus)
species showed the most potent antibacterial activity and
exhibited larger zone of inhibition on B. pseudomallei (Fig.
1) than the venoms of a viperid, D. russelli russelli and an
Australian elapid, Pseudechis australis. Crotalid venoms
have previously been reported to have broad activity
against aerobic gram-positive and negative bacteria [36],
but this is the first report showing the potent antibacterial
property of C. adamanteus venom against the drug resist-
ant B. pseudomallei. The antibacterial effects of crotalid,
viperid and elapid venoms established in the present
study may likely be due to the cyto-toxins (direct lytic fac-
tors) and phospholipase A2 enzymes contained in those
venoms [37]. Association between L-amino acid oxidase
activity (LAAO1 and LAAO2) and antibacterial property
of Pseudechis australis venoms has previously been sug-
gested [19]. However, according to our results, the 5 dif-
ferent venoms of C. adamanteus, Daboia russelli russelli, P.
australis, P. guttata and A. halys exhibited stronger antimi-
crobial activity against both strains of B. pseudomallei than
that shown by the L-amino acid oxidase enzymes of C.
adamanteus  and  B. atrox venoms, thus suggesting that
LAAO activity alone may not be solely responsible for the
antibacterial activity of these venoms.
In the present study, we have therefore tested a variety of
phospholipase A2 enzymes purified from different snake
venoms against Burkholderia pseudomallei, and have found
Antimicrobial activities of crude venoms (each disc contained  20 μl of 100 μg/ml) of different snake species tested against  gram-negative Burkholderia pseudomallei Figure 1
Antimicrobial activities of crude venoms (each disc contained 
20 μl of 100 μg/ml) of different snake species tested against 
gram-negative Burkholderia pseudomallei. Following 24 h incu-
bation at 37°C, zone of inhibition given by each venom was 
compared with that of the standard drug chloramphenicol 
(30 μg/disc). Inhibition zones against Burkholderia pseudomallei 
given by venoms of: (A) Daboia russelli russelli, (B) Agkistrodon 
halys, (C) Crotalus adamanteus, (D) Bitis gabonicarhinoceros. 
Rough wrinkled morphological features of gram-negative Bur-
kholderia pseudomallei bacteria were grown on Tryptic Soy 
agar plates at 37°C. (E) bacilli after 36 h incubation, (F) prom-
inent bacilli after 72 h incubation.BMC Infectious Diseases 2006, 6:100 http://www.biomedcentral.com/1471-2334/6/100
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Table 1: Antibacterial properties of animal venoms tested against Burkholderia pseudomallei at 0.1 mg/mL concentration.
Common name Scientific name Phospholipase A2 enzymatic 
activity
Yield of 
protein 
(mg/mL)
Micro-organisms
Total activity 
(μmoles/min)
Specific activity 
(μmoles/min/
mg protein)
B. pseudomallei 
(KHW)
B. pseudomallei 
(TES)
Elapidae
Death adder Acanthophis augtra 3.74 74.5 ± 0.5 0.1 - -
Common death adder Acanthophis antarcticus 190 487.5 ± 0.96 0.78 16.6 ± 0.43 14.3 ± 0.34
Northern death adder Acanthophis praelongus 241.2 1416 ± 3.84 0.34 8.90 ± 0.23 8.47 ± 0.21
Desert death adder Acanthophis pyrrhus 138 1150 ± 0.98 0.24 14.7 ± 0.23 16.5 ± 0.32
Hector Androctonus australis 22.2 85.2 ± 0.27 0.52 - 8.13 ± 0.14
Malayan krait Bungarus candidus 34.9 166.3 ± 0.56 0.42 - -
Sea snake Hydrophis cyanocinctus 3.3 40.5 ± 0.56 0.16 - -
Indian cobra Naja naja naja 293.4 1333 ± 1.7 0.44 12.2 ± 0.16 10.2 ± 0.09
Kreft's tiger snake Notechis aterater 41.96 183.1 ± 0.59 0.46 - -
Spitting cobra Naja sumatrana 406.5 903.5 ± 0.6 0.90 - -
Cobra Naja kaouthia 228.4 1904 ± 3.8 0.24 8.17 ± 0.15 -
King brown snake Pseudechis australis 434.5 3949 ± 3.2 0.22 27.7 ± 0.13 29.8 ± 0.105
Speckled brown snake Pseudechis guttata 308.5 791 ± 2.0 0.78 25.4 ± 0.19 26.8 ± 0.109
Red-bellied black snake Pseudechis porphyriacus 726.7 3303 ± 1.7 0.44 16.8 ± 0.15 14.2 ± 0.17
Collett's snake Pseudechis colletti 15.7 111.8 ± 0.89 0.28 - -
- Pseudonaja inframaggula 1995 5945 ± 26.6 0.66 7.7 ± 0.16 8.32 ± 0.11
Western brown snake Pseudonaja nuchalis 162.8 361.8 ± 0.6 0.90 8.2 ± 0.08 9.30 ± 0.11
Eastern brown snake Pseudonaja textilis 416.8 832.3 ± 0.6 1 14.2 ± 0.09 8.10 ± 0.14
Dugite Pseudechis affinis 218.7 376.8 ± 0.9 1.16 - -
Tiger keelback Rhabdophis tigrinus 36.3 259.1 ± 0.42 0.28 - -
The coastal taipan Oxyuranus scutellatus 1275.7 6075 ± 0.98 0.63 - -
Viperidae
Pallas Agkistrodon halys 86.5 157.4 ± 0.20 1.1 20.4 ± 0.14 26.4 ± 0.08
Puff adder Bitis arietans 124.1 248.2 ± 0.27 0.54 18.2 ± 0.16 16.2 ± 0.17
West African gaboon viper Bitis gabonica rhinoceros 126.5 452.4 ± 0.57 0.56 16.0 ± 0.19 14.5 ± 0.26
Common lancehead snake Bothrops atrox (L-amino acid oxidase) 3.8 6.36 ± 0.06 1.2 24.4 ± 0.19 26.2 ± 0.19
South American rattlesnake Crotalus adamanteus (L-amino acid 
oxidase)
34.2 201.3 ± 0.21 0.34 25.4 ± 0.208 23.4 ± 0.18
South American rattlesnake Crotalus adamanteus 236.4 619.4 ± 0.46 1.56 30.0 ± 0.23 28.3 ± 0.23
Saw-scaled viper Echis carinatus 53.4 106.5 ± 0.49 1.4 8.0 ± 0.14 7.5 ± 0.15
Indian Russell's viper Daboia russelli russelli 392.8 785.2 ± 0.40 1.36 29.9 ± 0.12 28.6 ± 0.16
Burmese Russell's viper Daboia russelli siamensis 262.4 524.4 ± 0.44 1.24 16.2 ± 0.15 15.6 ± 0.18
Wagler's pit viper Trimeresurus wagleri 4.6 38.2 ± 0.26 0.24 15.1 ± 0.14 16.3 ± 0.14
Apiidae
Honeybee venom Apis mellifera 3.7 20.5 ± 0.1 0.36 7.22 ± 0.23 12.3 ± 0.21
Scorpionidae
Black scorpion Androctonus crasicuda 3.6 69.5 ± 0.3 0.104 - -
Scorpion Buthotus hottenlota 4.4 10.4 ± 0.2 0.86 - -
Scorpion Buthotus hottenota hottenota 5.1 38.8 ± 0.1 0.26 - -
Chinese red scorpion Buthus martensii Karsch. 4.6 90.4 ± 0.2 0.102 - -
Ceftazidime (CF) 30 μg/disc - - - 28.9 ± 0.56 31.7 ± 0.78
Chloramphenicol (C) 30 μg/disc - - - 28.5 ± 0.37 30.0 ± 0.12
Streptomycin (S) 10 μg/disc - - - 27.3 ± 0.25 26.4 ± 0.29
Values of Phospholipase A2 enzymatic activity (μmoles/min/mg protein) are presented as mean ± S.D. (n = 10) of ten replicates.
*The values given as mean ± S.D. (n = 5) represent a venom inhibition zone in mm, including the 7 mm diameter of the disc, after 24 h incubation. 
The bacterial inoculum per plate contained 3.2 × 108 colony forming units (cfu/mL) which were spread onto the TS agar surface with sterile cotton 
swap. Sterile paper discs (7 mm diameter) were placed onto the TS agar surface and 20 μL of venom solution (0.1 mg/mL) added. Micro-organisms: 
B.p (KHW)-Burkholderia pseudomallei (KHW) and B.p (TES) Burkholderia pseudomallei (TES), Control (0); No activity (-), Drug controls: 
Chloramphenicol (30 μg/disc); Ceftazidime (30 μg/disc); Streptomycin (10 μg/disc).BMC Infectious Diseases 2006, 6:100 http://www.biomedcentral.com/1471-2334/6/100
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that crotoxin B and daboiatoxin display the strongest anti-
bacterial activity against both the strains of B. pseudomallei
(KHW & TES) (Table 2). Crotoxin B is a basic neurotoxic
phospholipase A2 (Crotalus durissus terrificus) containing
three chain protein that enhances the lethal potency of
crotoxin [38], while daboiatoxin is a monomeric PLA2
(Daboia russelli siamensis) with strong neurotoxic and
myotoxic activities [30]. Moreover, mulgatoxin (myotoxic
PLA2 of P. australis) and bee (Apis mellifera) venom PLA2
have also been found to exert significant antibacterial
activity against both strains (KHW & TES) of B. pseudoma-
llei.
The PLA2 enzymes showing potent inhibitory activity were
further studied for minimum inhibitory concentrations
(MICs) (Fig. 2, 3). Among those examined, the two puri-
fied PLA2 enzymes (crotoxin B and daboiatoxin) showed
stronger inhibitory activity at a lower dilution (MICs 0.25
mg/mL) against B. pseudomallei (TES) than melittin and
mulgatoxin. The two isolates (TES and KHW) of B. pseu-
domallei showed various levels of sensitivity to the two
PLA2 toxins with MICs ranging between 0.5 and 0.03125
mg/ml. The susceptibility of crotoxin B (69%) and daboi-
atoxin (63%) against TES was more or less equal to that of
chloramphenicol and ceftazidime against TES (Table 3).
The antibiotics chloramphenicol (70%) and ceftazidime
(80%) were highly susceptible against B. pseudomallei TES
& KHW, but MIC breaking points of antibiotics were
recorded at the lowest dilution (MICs 0.125 mg/mL) than
the PLA2 toxins. Our results corroborate with the previous
report on the conventional four-drug regimen which has
been replaced by ceftazidime for acute treatment. How-
ever, the chlroarmphenicol has also been given for the
first 8 weeks of oral treatment [39]. In the present study,
the antibiotic activity was gradually declined at the dilu-
tion 0.03125 mg/mL against B. pseudomallei (KHW) and
(TES). The rate of resistance of ceftazidime and chloram-
phenicol against KHW was 20% and 30%, respectively. In
a randomised trial previously reported, 161 severe mel-
oidosis patients were treated with ceftazidime (120 mg/
kg) + chloramphenicol (100 mg/kg) + doxycycline (4 mg/
kg) + TMP/SMX for less than 7 days. The mortality was
37% for ceftazidime and 74% for chloramphenicol [40].
However, in our study, melittin was slightly more active
than mulgatoxin against B. pseudomallei (strain KHW) at
MIC 0.25 mg/mL. It showed very weak MICs (Fig. 2, 3)
when compared with chloramphenicol and ceftazidime.
Other PLA2s (ammodytoxin A, Mojave toxin, β-bungaro-
toxin and taipoxin) however, lacked any activity against
both isolates of B. pseudomallei at all tested dilutions (0.5
– 0.03125 mg/mL). Based on previous studies using cati-
onic antibacterial peptides, cathelicidin-derived peptides
had modest MIC against S. maltophilia and A. xylosoxidans
(1.0 to > 32 mg/mL), but none inhibited Burkholderia
cepacia [41]. Moreover, another cationic peptide (hBD-3)
that was proven highly or intermediately effective (MBCs
>100 μg/mL) against 23 tested strains did not show any
effect against Burkholderia cepacia at 50 μg/mL [42]. When
the MIC of peptide D2A21 was compared with that of the
tracheal antimicrobial peptide (TAP), the former peptide
displayed greater potency than TAP against P. aeruginosa at
0.125 – 4 mg/mL, S. aureus at 0.25 – 4 mg/mL, and Bur-
kholderia cepacia at 32 to >64 mg/mL, respectively [43].
Relative to the MIC of these cationic antimicrobial pep-
tides, crotoxin B appears to have a much lower dose (MIC
0.25 mg/mL) against B. pseudomallei. MIC value of PLA2s
are more or less equally comparable to that of ceftazidime
(MICs 0.125 mg/mL), a drug of choice for melioidosis
infections in humans. The rat model of lung infection (14
days) showed that the B. cenocepacia LPS inner core oli-
Table 2: In vitro antibacterial activity of purified phospholipase A2 enzymes from snake venoms.
Phospholipase A2
enzymes (PLA2s)
Snake species (Scientific name) Mol. wt.(kDa) Conc. (mg/mL) Micro-organisms
B. pseudomallei 
(Strain KHW)
B. pseudomallei 
(Strain TES)
Crotoxin A (CA) Crotalus durissus terrificus 23.5 0.5 mg/mL - -
Crotoxin B (CB) Crotalus durissus terrificus 23.5 0.5 mg/mL 24.8 ± 0.089 27.6 ± 0.133
Ammodytoxin A Vipera ammodytes ammodytes 13.8 0.5 mg/mL - -
Mojave toxin Crotalus scutulatus scutulatus 23.5 0.5 mg/mL - -
β-Bungarotoxin Bungarus multicinctus 20.5 0.5 mg/mL - -
Taipoxin Oxyuranus scutellatus scutellatus 45.6 0.5 mg/mL -
Mulgatoxin Pseudechis australis 13.2 0.5 mg/mL 20.5 ± 0.075 22.7 ± 0.117
Daboiatoxin (DbTx) Daboia russelli siamensis 15.0 0.5 mg/mL 24.8 ± 0.103 26.2 ± 0.121
Bee venom PLA2 Apis mellifera 19.0 0.5 μg/mL 18.3 ± 0.089 20.4 ± 0.075
*The values given represent a venom inhibition zone in mm, including the 7 mm diameter of the disc, after 24 h incubation. The bacterial inoculum 
per plate contained 3.2 × 108 cfu/mL forming units which were spread onto the TS agar surface with sterile cotton swap. Sterile paper discs (7 mm 
diameter) were placed onto the TS agar surface and 20 μL of enzymes (0.5 mg/ml concentration) added, Control (0); No activity (-).BMC Infectious Diseases 2006, 6:100 http://www.biomedcentral.com/1471-2334/6/100
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Phospholipase A2 activity against pathogen from patients with KHW Figure 2
Phospholipase A2 activity against pathogen from patients with KHW. Micro-dilution technique was used to test the MICs of 
PLA2s as compared to that of the antibiotics. The values are the optical density read at 560 nm (means ± S.D.) from a single 
experiment performed in triplicates.BMC Infectious Diseases 2006, 6:100 http://www.biomedcentral.com/1471-2334/6/100
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gosaccharide is needed for resistance to three structurally
unrelated antimicrobial peptides for in vivo survival in a
rat model of chronic lung infection [44].
When PLA2 activity was examined, the highest activity
was found in the Australian elapid venoms (Oxyuranus
scutellatus>Pseudonaja inframaggula) followed by Pseu-
dechis australis, Pseudechis porphyriacus, Naja kaouthia,
Naja naja naja, Acanthophis praelongus and Acanthophis
pyrrhusrespectively. In contrast, the remaining venoms of
the Apiidae and Scorpionidae showed relatively less phos-
pholipase A2 activity than the viperidae venoms (Table
1).
The survival bar resulting from the XTT assay shows that
all five venoms (C. adamanteus, B. gabonica, P. australis, D.
russelli russelli and A. halsy )do not have cytotoxic effects
on the proliferation of cells up to 0.5 mg/mL concentra-
tion (Fig. 4a–e). However, the higher concentrations (1, 5
and 10 mg/mL) showed severe morphological changes of
the cell lines such as membrane disruption and significant
cell lyses when compared with control and the positive
Phospholipase A2activity against pathogen from patients with TES Figure 3
Phospholipase A2activity against pathogen from patients with TES. Micro-dilution technique was used to test the MICs of PLA2s 
as compared to that of the antibiotics. The values are the optical density read at 560 nm (means ± S.D.) from a single experi-
ment performed in triplicates.BMC Infectious Diseases 2006, 6:100 http://www.biomedcentral.com/1471-2334/6/100
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control (Fig. 5). In contrast, the purified PLA2s, crotoxin B
and daboiatoxin, did not change the viability (Fig. 4f–g)
of cells up to 0.05 – 10 μg/mL concentrations as com-
pared to the control. The cell viability and morphology of
macrophage cells were shown (Fig. 6) after exposure to
crotoxin B in a dose- and time-dependent manner.
A comparison of the N-terminal sequences of crotoxin B
with other snake venom PLA2s shows (Fig. 7) that most
amino acid residues are conserved in Ca+2 binding and
catalytic network regions. The C-terminal segment of cro-
toxin B, on the other hand, shows a modest difference in
the amino acid residues as compared with the C-terminal
sequences of other venom PLA2s. Moreover, comparison
of the hydropathic profiles of different snake venom
PLA2s reveals that the C-terminal segment of crotoxin B is
relatively more hydrophobic than those of other PLA2s
(Fig. 8). This cationic hydrophobic nature of crotoxin B
phospholipase A2 enzyme may most likely be responsible
for the strong antimicrobial action seen on B. pseudoma-
llei.
Conclusion
The present study indicates that the purified PLA2
enzymes (crotoxin B, daboiatoxin) possess strong antibac-
terial activity against B. pseudomallei. The fact that viperi-
dae (Crotalus adamanteus, Daboia russelli russelli) and
elapidae (Pseudechis australis) venoms display more
potency than other venoms may be due to the PLA2
enzymes present. However, this antibacterial profile of
snake venoms reported herein will be useful in the search
for potential antibacterial agents against drug resistant
microorganisms like B. pseudomallei.
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Table 3: MIC breakpoints for ceftazidime and chloramphenicol when compared to that of purified PLA2s enzymes.
Phospholipase A2
enzymes (PLA2s)
MIC 
mg/mL
B. pseudomallei (strain KHW) MIC 
mg/mL
B. pseudomallei (strain TES)
Ctrl 0.5 0.25 0.125 0.0625 0.03125 Ctrl 0.5 0.25* 0.125a 0.0625 0.03125
Crotoxin B (CB) 0.65 0.012 
(64%)
0.04 
(61%)
0.33 
(32%)
0.43 
(32%)
0.56 
(9%)
0.73 0.05 
(73%)
0.06 
(69%)
0.33 
(40%)
0.43 
(30%)
0.52 
(21%)
Daboiatoxin (DbTx) 0.65 0.26 
(39%)
0.09 
(56%)
0.37 
(28%)
0.49 
(16%)
0.55 
(10%)
0.68 0.03 
(65%)
0.05 
(63%)
0.24 
(20%)
0.36 
(8%)
0.43 
(1%)
Bee venom PLA2 0.48 0.038 
(38%)
0.056 
(42%)
0.15 
(33%)
0.24 
(24%)
0.39 
(9%)
0.44 0.03 
(45%)
0.06 
(38%)
0.27 
(17%)
0.36 
(8%)
0.41 
(3%)
Mulgatoxin 0.46 0.07 
(39%)
0.083 
(37%)
0.21 
(25%)
0.28 
(18%)
0.39 
(7%)
0.43 0.04 
(40%)
0.07 
(37%)
0.26 
(18%)
0.32 
(12%)
0.37 
(7%)
Chloramphenicol 0.67 0.01 
(68%)
0.03 
(64%)
0.07 
(60%)
0.42 
(10%)
0.51 
(1%)
0.77 0.026 
(74%)
0.04 
(73%)
0.07 
(70%)
0.34 
(41%)
0.37 
(38%)
Ceftazidime 0.76 0.08 
(58%)
0.05 
(61%)
0.04 
(62%)
0.24 
(24%)
0.44 
(22%)
0.89 0.01 
(88%)
0.03 
(86%)
0.09 
(80%)
0.35 
(47%)
0.49 
(33%)
* MIC values are given as mean of five replicates (n = 5), the bacterial inoculums per plate contained 3.2 × 108 cfu/mL forming units/well, Control 
(bacterial inoculums); aThe ceftazidime breaking points (MICs 0.125 mg/mL) against TES, *The PLA2 toxin breaking points (MICs 0.250 mg/mL) 
against both the strains of B. pseudomallei after 24 h incubation.BMC Infectious Diseases 2006, 6:100 http://www.biomedcentral.com/1471-2334/6/100
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Cell proliferation (U-937 Human macrophage cell line) was determined by XTT assay to evaluate the cytotoxic effect of differ- ent venoms (a – e) and PLA2s (f – j) exposed at different time intervals Figure 4
Cell proliferation (U-937 Human macrophage cell line) was determined by XTT assay to evaluate the cytotoxic effect of differ-
ent venoms (a – e) and PLA2s (f – j) exposed at different time intervals. (a) South American rattlesnake (Crotalus adamanteus), 
(b) Russells viper (Daboia russelli russelli), (c) King brown (Pseudechis australis), (d) Pallas (Agkistrodon halys) (e) Speckled brown 
(Pseudechis guttata) (f) Crotoxin B (Crotalus durissus terrificus), (g) Daboiatoxin (Daboia russelli russelli), (h) Melittin (Apis mellifera), 
(i) Mulgatoxin (Pseudechis australis) (j) Crotoxin A (Crotalus durissus terrificus). Macrophages were incubated with varying con-
centrations of venoms (0.05 – 10 mg/ml) and PLA2s (0.05 – 10 μg/ml).BMC Infectious Diseases 2006, 6:100 http://www.biomedcentral.com/1471-2334/6/100
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Morphological changes of U-937 Human macrophage cell line after exposure to Crotalus adamanteus venom at different con- centrations Figure 5
Morphological changes of U-937 Human macrophage cell line after exposure to Crotalus adamanteus venom at different con-
centrations. (Ctrl) macrophage supplemented with medium without any treatment served as control; (PC), cells exposed with 
ceftazidime as a positive control. Macrophages were incubated with venom at different (0.05–10 mg/mL) concentrations 
(Other photos not shown).BMC Infectious Diseases 2006, 6:100 http://www.biomedcentral.com/1471-2334/6/100
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Morphological changes of U-937 Human macrophage cell line after exposure to PLA2s at varying concentrations (0.05–10 μg/ mL) Figure 6
Morphological changes of U-937 Human macrophage cell line after exposure to PLA2s at varying concentrations (0.05–10 μg/
mL). (Ctrl), control macrophages supplemented with medium without any treatment; (PC), cells exposed with ceftazidime as a 
positive control.BMC Infectious Diseases 2006, 6:100 http://www.biomedcentral.com/1471-2334/6/100
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Comparison of the amino acid sequences of Crotoxin basic chain 1, CB1 [Crotalus durissus terrificus] phospholipase A2 enzymes  (Phosphatidylcholine 2-acylhydrolase) with other PLA2s of Mojave toxin basic chain, Mtx-b [Crotalus scutulatus scutulatus], Cro- toxin basic chain 2, CB2 [Crotalus durissus terrificus], Agkistrotoxin, ATX [Agkistrodon halys], VRV-PL-VIIIa [Daboia russelli  pulchella], BOTAS (Myotoxin I) Bothrops asper (Terciopelo), ATXA, ammodytoxin A precursor [Vipera ammodytes ammodytes];  RVV-VD [Daboia russelli russelli]; RV-4 precursor [Daboia russelli siamensis], BOTAS (Myotoxin II) [Bothrops asper], BOTJR  (BthTX-I) [Bothrops jararacussu], ECHCA (Ecarpholin S) [Echis carinatus (Saw-scaled viper)], Crotoxin acid chain precursor  (CA) [Crotalus durissus terrificus], β-bungarotoxin A6 chain precursor [Bungarus multicinctus (Many-banded krait)] and OXYSC  taipoxin alpha chain [Oxyuranus scutellatus scutellatus] and completely conserved residues in all sequences are bolded and  marked by asterisks Figure 7
Comparison of the amino acid sequences of Crotoxin basic chain 1, CB1 [Crotalus durissus terrificus] phospholipase A2 enzymes 
(Phosphatidylcholine 2-acylhydrolase) with other PLA2s of Mojave toxin basic chain, Mtx-b [Crotalus scutulatus scutulatus], Cro-
toxin basic chain 2, CB2 [Crotalus durissus terrificus], Agkistrotoxin, ATX [Agkistrodon halys], VRV-PL-VIIIa [Daboia russelli 
pulchella], BOTAS (Myotoxin I) Bothrops asper (Terciopelo), ATXA, ammodytoxin A precursor [Vipera ammodytes ammodytes]; 
RVV-VD [Daboia russelli russelli]; RV-4 precursor [Daboia russelli siamensis], BOTAS (Myotoxin II) [Bothrops asper], BOTJR 
(BthTX-I) [Bothrops jararacussu], ECHCA (Ecarpholin S) [Echis carinatus (Saw-scaled viper)], Crotoxin acid chain precursor 
(CA) [Crotalus durissus terrificus], β-bungarotoxin A6 chain precursor [Bungarus multicinctus (Many-banded krait)] and OXYSC 
taipoxin alpha chain [Oxyuranus scutellatus scutellatus] and completely conserved residues in all sequences are bolded and 
marked by asterisks. The gaps are inserted in the sequences in order to attain maximum homology.BMC Infectious Diseases 2006, 6:100 http://www.biomedcentral.com/1471-2334/6/100
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Hydropathic profiles of phospholipase A2 enzyme such as crotoxin b, daboiatoxin, mulgatoxin, taipoxin, ammodytoxin A, bee  venom PLA2, beta-bungarotoxin and mojavetoxin were calculated by using the kyte-doolittle method Figure 8
Hydropathic profiles of phospholipase A2 enzyme such as crotoxin b, daboiatoxin, mulgatoxin, taipoxin, ammodytoxin A, bee 
venom PLA2, beta-bungarotoxin and mojavetoxin were calculated by using the kyte-doolittle method.BMC Infectious Diseases 2006, 6:100 http://www.biomedcentral.com/1471-2334/6/100
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